Your session is about to expire
← Back to Search
Pimavanserin vs. Quetiapine for Psychosis in Parkinson's Disease (C-SAPP Trial)
C-SAPP Trial Summary
This trial will compare the safety and effectiveness of Quetiapine and Pimavanserin in Veterans with Parkinson's disease psychosis.
C-SAPP Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowC-SAPP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.C-SAPP Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had a mental health condition like schizophrenia or bipolar disorder before Parkinson's disease.My psychosis is due to a toxic or metabolic disorder.I couldn't tolerate quetiapine or pimavanserin.I had DBS surgery less than 6 months ago or adjusted my stimulator last month.I have been diagnosed with Parkinson's Disease.I've been on a stable dose of an acetylcholinesterase inhibitor for at least 4 months.I might have an unusual form of Parkinson's or dementia with Lewy bodies.I am currently on medication that affects how my body processes drugs.I haven't taken any antipsychotic drugs except for low-dose quetiapine, which I stopped over a month ago.I am currently living in a nursing home or will be during the study.You understand what the study is about and agree to participate.I am not pregnant and willing to use contraception if I can have children.You are already participating in another study involving medication or treatment.You currently have severe mental health symptoms that require immediate treatment and prevent you from participating in the study.I have a history of irregular heartbeats that are not under control.You have served in the military.I am 18 years old or older.My caregiver is over 18, agrees to the study terms, and spends significant time with me daily.I am 40 years old or older.I have a history of long QT syndrome.I am taking medication that affects my heart's electrical cycle.My Parkinson's disease medication dose has been stable for at least a month.You are currently having suicidal thoughts or planning to harm yourself.I experience strong hallucinations or delusions.
- Group 1: Quetiapine
- Group 2: Pimavanserin 34mg
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 2 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 4 Months
- Follow Ups: You may be asked to continue sharing information regarding the trial for 2 Weeks after you stop receiving the treatment.
Frequently Asked Questions
Are there still open spots in this clinical research endeavor?
"Affirmative. Clinicaltrials.gov has the information that confirms this clinical trial, which opened on October 24th 2022 is actively enrolling participants. 358 patients are sought from 25 different medical locations."
How is the medication Pimavanserin 34mg typically employed to assist patients?
"Pimavanserin 34mg is a popular treatment for Parkinson's disease Psychosis, as well as Major Depressive Disorder (MDD), Anxiety Disorders, and Acute Coryza."
How many venues are offering participation in this research project?
"Currently, 25 clinical trial sites are recruiting patients for the study; prominent locations include San Francisco, Loma Linda and Palo Alto. To ease any transportation burdens that may come with enrollment, consider selecting a clinic near you."
Are there any prior instances of administering Pimavanserin 34mg as part of a clinical trial?
"Originally trialled in 2014 at UT Southwestern Medical Centre, pimavanserin 34mg has since been tested 193 times. 18 of those trials are currently ongoing with the majority taking place within San Francisco, California."
Has a similar trial been conducted before this one?
"Since 2014, Pimavanserin 34mg has undergone extensive clinical research. The first trial was conducted by Otsuka America Pharmaceutical and completed in the same year with 200 patients enrolled. Following this initial study, it received Phase 4 drug approval and is currently being tested across 189 cities over 33 countries in 18 live trials."
What is the sample size of participants involved in this research endeavor?
"This clinical trial requires 358 suitable candidates to be enrolled. Locations in San Francisco, California and Loma Linda, Florida are both offering this medical research opportunity which adheres to the specified inclusion criteria."
Is Pimavanserin 34mg a risk to the health of those who take it?
"Pimavanserin 34mg is confirmed to be safe, thus it was assigned a value of 3 on our scale. This determination was made due to the drug having already passed Phase 4 clinical trials and being approved for use."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger